Free tool
FAERS Monitor: Selenious Acid
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209379 or its brand name (Selenious Acid, Selenious Acid). Reports on generic versions are filed under their own applications.
Reports
12
Serious
11
92% of reports
Hospitalization
4
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- plasma cell myeloma5
- diarrhoea2
- cerebral palsy1
- cholangitis1
- circumstance or information capable of leading to medication error1
- fatigue1
- hypersensitivity1
- infection1
- internal haemorrhage1
- nausea1
- neuropathy peripheral1
- pneumonia1
- product label confusion1
- respiratory failure1
- wrong dose1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2014 | 1 |
| 2017 | 1 |
| 2020 | 1 |
| 2023 | 4 |
| 2024 | 2 |
| 2026 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,147 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cerebral palsy | 1 | 1846.9 | 282.5 | 460 |
| wrong dose | 1 | 725.3 | 111.0 | 180 |
| product label confusion | 1 | 300.8 | 46.0 | 74 |
| cholangitis | 1 | 282.8 | 43.3 | 70 |
| plasma cell myelomaSignal | 5 | 224.6 | 115.0 | 902 |
| internal haemorrhage | 1 | 153.4 | 23.5 | 37 |
| circumstance or information capable of leading to medication error | 1 | 51.9 | 7.9 | 12 |
| respiratory failure | 1 | 24.0 | 3.7 | 5 |
| neuropathy peripheral | 1 | 18.4 | 2.8 | 4 |
| infection | 1 | 12.1 | 1.9 | 2 |
| hypersensitivity | 1 | 9.4 | 1.4 | 1 |
| diarrhoea | 2 | 5.4 | 1.5 | 4 |
| pneumonia | 1 | 5.4 | 0.8 | 1 |
| fatigue | 1 | 2.3 | 0.3 | 0 |
| nausea | 1 | 2.2 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.